Three gene editing startups, Intellia Therapeutics, Caribou Biosciences and CRISPR Therapeutics, have signed an agreement surrounding the intellectual property of the hotly contested revolutionary gene editing technology CRISPR/Cas9. The companies have entered into the deal with Emmanuelle Charpentier of the Helmholtz Centre and the University of California. In a press release, Intel said that it has been working on this project for more than two years now to develop technologies that will enable scientists to use CRISPR-Cas9 in human cells. Many will see this move as a hedge against any potential fallout from the current patent lawsuit between MIT/Harvard and UC Berkeley for the IP rights to CRISPR/Cas9, which may total many billions of dollars.
Three gene editing startups, Intellia Therapeutics, Caribou Biosciences and CRISPR Therapeutics, have signed an agreement surrounding the intellectual property of the hotly contested revolutionary gene editing technology CRISPR/Cas9. The companies have entered into the deal with Emmanuelle Charpentier of the Helmholtz Centre and the University of California. The deal encourages all parties to enforce and protect CRISPR's IP and clarifies the worldwide IP position of its signatories. Many will see this move as a hedge against any potential fallout from the current patent lawsuit between MIT/Harvard and UC Berkeley for the IP rights to CRISPR/Cas9, which may total many billions of dollars.